-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Latest research results of Penn University: A single injection of RNA drugs can improve vision for 15 monthsYimaihei Technology ★ treats "gradual freezing"! Ionis' antisense drug enters clinical phase 3MedMeng broke the news on April 12, 2021/eMedClub News/--Phio Pharmaceuticals (Nasdaq: PHIO) recently announced at the 2021 American Association for Cancer Research (AACR) annual meeting In poster format, the latest research data of the product mPH-762 developed based on its proprietary "Self-delivering" RNAi platform INTASYL™, titled "Intratumoral injection of INTASYL™ targeting PD-1 self-delivered RNAi drugs , Provides in vivo tumor control and tumor microenvironment regulation comparable to anti-PD-1 antibody system therapy.
"INTASYL™ platform (formerly known as sd-rxRNA) is a hybrid oligonucleotide compound with a single-chain phosphorothioate region , Short double-stranded region, and contains a variety of nuclease stabilization and hydrophobic chemical modification.
These chemical modifications give it stability, effective cell uptake and reduce inflammation; at the same time, it makes INTASYL™ compounds do not require delivery mechanisms or delivery technologies, that is, cells can automatically take up INTASYL™ without the need for delivery vehicles.
Phio believes that INTASYL™ combines the advantages of traditional RNAi and antisense technology.
Traditional single-stranded antisense compounds have good tissue distribution and cell absorption characteristics, but do not have the intracellular efficacy of double-stranded RNAi compounds; while the double-stranded structure and hydrophilic properties of traditional RNAi compounds lead to tissue diffusion and cell malabsorption.
In addition, for almost all targets, INTASYL™ can produce high knockout efficiency, and its highly active compounds have also been proven to last for several months, so it is selected for preclinical and clinical research and development.
▲ The characteristics of INTASYL™ (picture source: phiopharma.
com) is based on the PD-1 targeting product mPH-762 developed by INTASYL™.
The latest in vivo data released this time show that mPH-762 is administered by intratumoral injection, whether in Both PD-1 responsiveness and refractory mouse models can inhibit tumor growth in a dose-dependent manner.
In addition, the data also proves that mPH-762 can achieve on-target efficacy by regulating the anti-tumor immune cell population.
The company believes that these data further support that INTASYL mPH-762 has a strong local immune checkpoint blocking (ICB) potential, and does not have immune-related adverse reactions (irAEs) seen in the systemic administration of ICB antibodies.
Phio plans to conduct the first-in-human clinical study of PH-762 directly administered for patients with advanced melanoma at the Gustave Roussy Institute in the fourth quarter of 2021 .
The 2021 nucleic acid drug development forum will kick off in Nanjing from May 7th to 8th, 2021, to welcome the "new era of super drugs".
"INTASYL™ platform (formerly known as sd-rxRNA) is a hybrid oligonucleotide compound with a single-chain phosphorothioate region , Short double-stranded region, and contains a variety of nuclease stabilization and hydrophobic chemical modification.
These chemical modifications give it stability, effective cell uptake and reduce inflammation; at the same time, it makes INTASYL™ compounds do not require delivery mechanisms or delivery technologies, that is, cells can automatically take up INTASYL™ without the need for delivery vehicles.
Phio believes that INTASYL™ combines the advantages of traditional RNAi and antisense technology.
Traditional single-stranded antisense compounds have good tissue distribution and cell absorption characteristics, but do not have the intracellular efficacy of double-stranded RNAi compounds; while the double-stranded structure and hydrophilic properties of traditional RNAi compounds lead to tissue diffusion and cell malabsorption.
In addition, for almost all targets, INTASYL™ can produce high knockout efficiency, and its highly active compounds have also been proven to last for several months, so it is selected for preclinical and clinical research and development.
▲ The characteristics of INTASYL™ (picture source: phiopharma.
com) is based on the PD-1 targeting product mPH-762 developed by INTASYL™.
The latest in vivo data released this time show that mPH-762 is administered by intratumoral injection, whether in Both PD-1 responsiveness and refractory mouse models can inhibit tumor growth in a dose-dependent manner.
In addition, the data also proves that mPH-762 can achieve on-target efficacy by regulating the anti-tumor immune cell population.
The company believes that these data further support that INTASYL mPH-762 has a strong local immune checkpoint blocking (ICB) potential, and does not have immune-related adverse reactions (irAEs) seen in the systemic administration of ICB antibodies.
Phio plans to conduct the first-in-human clinical study of PH-762 directly administered for patients with advanced melanoma at the Gustave Roussy Institute in the fourth quarter of 2021 .
The 2021 nucleic acid drug development forum will kick off in Nanjing from May 7th to 8th, 2021, to welcome the "new era of super drugs".
